BONIVA Injection Tolerability

Tolerability of BONIVA—1-year results from DIVA Trial

Enlarge chart

The overall AE profile for the quarterly injection was similar to the once-daily tablets
The overall AE profile for the 2.5-mg once-daily tablets was similar to placebo
Overall incidence of acute phase reaction-like (APR) events was 4% in the BONIVA Tablets group vs 10% in the BONIVA Injection group
- In most cases, no specific treatment was required and symptoms subsided in 24 to 48 hours
- For patients experiencing APR events, 80% of them occurred only with the first dose¹
Overall, BONIVA side effects were mild or moderate, transient, and resolved without treatment¹

Image: Gail M., Age 70, Forgets to take oral therapy

References:
1. Data on file (Ref. #161-159), Hoffmann-La Roche Inc., Nutley, NJ.

BONIVA Injection is indicated for the treatment of osteoporosis in postmenopausal women.

Important Safety Information for BONIVA Injection
BONIVA Injection is contraindicated in patients with uncorrected hypocalcemia or known hypersensitivity to BONIVA Injection or any of its excipients. BONIVA Injection, like other bisphosphonates administered intravenously, may cause a transient decrease in serum calcium values. Hypocalcemia, hypovitaminosis D, and other disturbances of bone and mineral metabolism must be effectively treated before starting therapy. Patients must receive supplemental calcium and vitamin D. BONIVA Injection must only be administered intravenously by a healthcare professional. Patients who receive BONIVA Injection should have serum creatinine measured prior to each dose. BONIVA Injection should not be administered to patients with severe renal impairment (creatinine clearance <30 mL/min). Rarely, patients have reported severe bone, joint and/or muscle pain after taking bisphosphonate therapy for osteoporosis. Osteonecrosis of the jaw has been reported in patients treated with bisphosphonates; most cases have been in cancer patients undergoing dental procedures who received intravenous bisphosphonates.

In a one-year study comparing BONIVA Injection 3 mg quarterly and BONIVA Tablets 2.5 mg daily, the overall safety and tolerability profiles with the two dosing regimens were similar. The most commonly reported adverse events (>5%) regardless of causality were arthralgia (9.6% BONIVA Injection vs 8.6% BONIVA Tablet 2.5 mg), back pain (7.0% vs 7.5%), hypertension (5.3% vs 7.1%), abdominal pain (5.1% vs 5.6%), influenza (4.7% vs 8.0%) and nasopharyngitis (3.4% vs 6.0%). In some patients acute phase reaction-like events (10% BONIVA Injection vs 4% BONIVA Tablets) have been reported within 3 days of an IV dose and lasting for 7 days or less, most commonly after the first injection. In most cases, no specific treatment was required and symptoms subsided in 24-48 hours.

This site is intended for U.S. residents only.

The information provided on this site is for informational purposes only and does not take the place of talking to your healthcare provider about your medical condition or treatment.

Privacy Policy | Legal Statement | Contact Us | Unsubscribe

BONIVA and symbol are trademarks of Roche Therapeutics Inc.
MyBONIVA is a registered trademark of Roche Therapeutics Inc.

GlaxoSmithKline